Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19.

Publication date: Mar 01, 2024

A subset of patients experiences persistent fatigue symptoms after COVID-19, and patients may develop long COVID, which is characterized by lasting systemic symptoms. No treatments for this condition have been validated and are urgently warranted. In this pilot study, we assessed whether treatment with low-dose naltrexone (LDN, 4. 5 mg/day) and supplementation with NAD + through iontophoresis patches could improve fatigue symptoms and quality of life in 36 patients with persistent moderate/severe fatigue after COVID-19. We detected a significant increase from baseline in SF-36 survey scores after 12 weeks of treatment (mean total SF-36 score 36. 5 [SD: 15. 6] vs. 52. 1 [24. 8]; p

Concepts Keywords
5mg COVID-19
Fatigue Fatigue
Immun Long COVID
Pilot Low dose naltrexone
Weeks NAD+
Quality of life
SF-36

Semantics

Type Source Name
disease VO dose
drug DRUGBANK Naltrexone
disease MESH COVID-19
disease MESH long COVID
disease IDO quality

Original Article

(Visited 1 times, 1 visits today)